A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-week Study to Investigate the Safety and Efficacy of Oral SPP635 450 mg Once Daily in Patients With Mild to Moderate Hypertensio
- Conditions
- mild to moderate hypertension
- Registration Number
- EUCTR2006-004176-13-DE
- Lead Sponsor
- Speedel Pharma Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with mild to moderate hypertension with blood pressures between 140 and 179 mmHg systolic, and 109 mmHg diastolic blood pressure (office blood pressure)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Women of childbearing potential
pregnant and lactating women
any current or past heart disease
any history of kidney failure
any history of diabetes mellitus
HbA1c > 6%
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method